BCAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Bicara Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$17.47+0.69 (+4.11%)
Close on Oct 19, 2026
- Market cap
- $1.19B
- P/E (TTM)
- –
- Dividend yield
- –
Bicara Therapeutics Inc. cash flow statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -30.9%
Financial strength
- Current ratio
- 11.59
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 222.2%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.53
- Dividend yield
- –